MIRM

In May 2026, Mirum reported strong first-quarter financial results and raised its full-year net product sales guidance. The company also announced positive topline results from the Phase 2b VISTAS study of volixibat and the Phase 2b portion of the AZURE-1 study of brelovitug. In January 2026, Mirum completed the acquisition of Bluejay Therapeutics, impacting Q1 operating expenses. In February 2026, the company's stock fell following the disclosure of a share offering. Mirum reported its fourth-quarter and full-year 2025 results, with a significant increase in total net product sales.